NCT00777699View on ClinicalTrials.gov

Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
CancerNon-Small Cell Lung Cancer
Interventions
DRUG

XL765 (SAR245409)

Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing

DRUG

erlotinib

Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing

Trial Locations (1)

19111

Investigational Site Number 168983, Philadelphia

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY